ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
March 12, 2025 07:57 ET
|
ZyVersa Therapeutics
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults.AD begins with...
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
March 06, 2025 08:00 ET
|
ZyVersa Therapeutics
WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
March 05, 2025 07:52 ET
|
ZyVersa Therapeutics
Inflammasome inhibition in obese animal model with heart failure was cardioprotective & improved metabolic parameters.
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
December 18, 2024 07:55 ET
|
ZyVersa Therapeutics
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
November 20, 2024 07:55 ET
|
ZyVersa Therapeutics
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
November 14, 2024 08:10 ET
|
ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
November 05, 2024 07:00 ET
|
ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
October 29, 2024 07:57 ET
|
ZyVersa Therapeutics
Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
October 22, 2024 07:57 ET
|
ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
October 17, 2024 07:50 ET
|
ZyVersa Therapeutics
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.